תחילת דף אינטרנט, לחץ אנטר כדי לעבור לאזור תוכן מרכזי
תפריט ראשי של האתר

Prof. Stephen Levine (PhD, MA, BSc)

slevine@univ.haifa.ac.il

Reception hours: By appointment

School of Public Health

Education

2004    Ph.D. Psychology, University of Surrey, UK

1998    MSc. Occupational Psychology, LGU, UK

1996    BSc. Psychology, LGU, UK

 

 

My research interests are in schizophrenia, autism spectrum disorders, dementia, cognition and psychiatric epidemiology which are examined with advanced psychometric and biostatistic techniques mostly in R or SAS, using observational and clinical trial study designs.

Peer-reviewed Journal Publications

  1. Levine SZ, Rotstein A, Kodesh A, Sandin S, Lee BK, Weinstein G, Schnaider Beeri M, Reichenberg, A. Adult Attention-Deficit/Hyperactivity Disorder and the Risk of Dementia. JAMA Netw Open. 2023;6(10):e2338088.
  2. Levine SZ, Rotstein A, Goldberg Y, Reichenberg A, Kodesh A. Opioid Exposure and the Risk of Dementia: A National Cohort Study. Am J Geriatr Psychiatry. 2023;31(5):315-323.
  3. Travis-Lumer Y, Goldberg Y, Kodesh A, Reichenberg A, Sandin S, Frangou S, Levine SZ. Rates of Spontaneous Abortion in Israel Before and During the COVID-19 Pandemic. JAMA Netw Open. 2023;6(2):e230233.
  4. Travis-Lumer Y, Kodesh A, Goldberg Y, Frangou S, Levine SZ. Attempted suicide rates before and during the COVID-19 pandemic: interrupted time series analysis of a nationally representative sample. Psychol Med. 2023;53:2485 - 2491.
  5. Frangou S, Travis-Lumer Y, Kodesh A, Goldberg, Y, New, F, Reichenberg, A, Levine, SZ. Increased incident rates of antidepressant use during the COVID-19 pandemic: interrupted time-series analysis of a nationally representative sample. Psychol Med. 2023;53(11):4943-4951.
  6. Leucht S, Dombi ZB, Szabo P, Barabassy A, Levine SZ. Single trajectory treatment response for predominant negative symptoms: Post-hoc analysis of a clinical trial with cariprazine and risperidone. Schizophr Res. 2023;261:24-30.
  7. Samara MT, Levine SZ, Leucht S. Linkage of Young Mania Rating Scale to Clinical Global Impression Scale to Enhance Utility in Clinical Practice and Research Trials. Pharmacopsychiatry. 2023;56(1):18-24.
  8. Khachadourian V, Kodesh A, Levine SZ, et al. Somatic comorbidities of mental disorders in pregnancy. European psychiatry. 2023;66(1):e15.
  9. Yin W, Norrback M, Levine SZ, et al. Maternal rheumatoid arthritis and risk of autism in the offspring. Psychol Med. 2023:1-9.
  10. Rotstein A, Fund S, Levine SZ, Reichenberg A, Goldenberg J. Is cognition integral to psychopathology? A population-based cohort study. Psychol Med. 2023:1-8.
  11. Vancak V, Goldberg Y, Levine SZ. The number needed to treat adjusted for explanatory variables in regression and survival analysis: Theory and application. Stat Med. 2022;41(17):3299-3320.
  12. Travis-Lumer Y, Kodesh A, Goldberg Y, Reichenberg A, Frangou S, Levine SZ. Biopsychosocial exposure to the COVID-19 pandemic and the relative risk of schizophrenia: Interrupted time-series analysis of a nationally representative sample. European psychiatry: the journal of the Association of European Psychiatrists. 2022;65(1):e7.
  13. Travis-Lumer Y, Goldberg Y, Levine SZ. Effect size quantification for interrupted time series analysis: implementation in R and analysis for Covid-19 research. Emerg Themes Epidemiol. 2022;19(1):9.
  14. Rotstein A, Shadmi E, Roe D, Gelkopf M, Levine SZ. Gender differences in quality of life and the course of schizophrenia: national study. BJPsych Open. 2022;8(2):e35.
  15. Rotstein A, Levine SZ, Samara M, et al. Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil. Eur Neuropsychopharmacol. 2022;57:50-58.
  16. Rotstein A, Kodesh A, Goldberg Y, Reichenberg A, Levine SZ. Serum folate deficiency and the risks of dementia and all-cause mortality: a national study of old age. Evid Based Ment Health. 2022;25(2):63-68.
  17. Levine SZ, Goldberg Y, Yoshida K, et al. Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. J Psychiatr Res. 2022;148:159-164.
  18. Eran-Jona M, Tiargan-Orr R, Levine SZ, Limor Y, Schenhav M, Ben-Shalom U. Habituation of Fear-Israeli-Jewish Population during Protracted Belligerence. Int J Environ Res Public Health. 2022;19(23).
  19. Weinstein Y, Gelkopf M, Roe D, Levine SZ. Terror exposure and psychiatric rehabilitation utilization: A national study of Jewish citizens in Israel. The Israel journal of psychiatry and related sciences. 2021;58(1):1-20.
  20. Vancak V, Goldberg Y, Levine SZ. Guidelines to understand and compute the number needed to treat. Evid Based Ment Health. 2021;24(4):131-136.
  21. Samara M, Levine SZ, Yoshida K, et al. Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician's Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil. J Alzheimers Dis. 2021;82(3):1075-1084.
  22. Rotstein A, Levine SZ. Childhood infectious diseases and old age cognitive functioning: a nationally representative sample of community-dwelling older adults. Int Psychogeriatr. 2021;33(1):75-82.
  23. Rotstein A, Goldenberg J, Fund S, Levine SZ, Reichenberg A. Capturing adolescents in need of psychiatric care with psychopathological symptoms: A population-based cohort study. European psychiatry : the journal of the Association of European Psychiatrists. 2021;64(1):e76.
  24. Reichenberg A, Levine SZ. Primary challenges and practical solutions in preventive psychiatry. World Psychiatry. 2021;20(2):228-230.
  25. Pijnenburg LJ, de Haan L, Smith L, et al. Early predictors of mental health in mid-adulthood. Early Interv Psychiatry. 2021;15(1):158-166.
  26. Pereira G, Francis RW, Gissler M, et al. Optimal interpregnancy interval in autism spectrum disorder: A multi-national study of a modifiable risk factor. Autism Res. 2021;14(11):2432-2443.
  27. Levine SZ, Yoshida K, Goldberg Y, et al. Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil. Evid Based Ment Health. 2021;24(2):56-61.
  28. Levine SZ, Goldberg Y, Yoshida K, et al. Quantifying the heterogeneity of cognitive functioning in Alzheimer's disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil. European psychiatry : the journal of the Association of European Psychiatrists. 2021;64(1):e16.
  29. Kodesh A, Levine SZ, Khachadourian V, et al. Maternal health around pregnancy and autism risk: a diagnosis-wide, population-based study. Psychol Med. 2021:1-9.
  30. Khatib A, Ben-David V, Gelkopf M, Levine SZ. Ethnic group and social support contribution to posttraumatic growth after sudden spousal loss among Jewish, Muslim, and Druze widows in Israel. J Community Psychol. 2021;49(5):1010-1023.
  31. Furukawa TA, Levine SZ, Buntrock C, et al. How can we estimate QALYs based on PHQ-9 scores? Equipercentile linking analysis of PHQ-9 and EQ-5D. Evid Based Ment Health. 2021;24(3):97-101.
  32. Furukawa TA, Levine SZ, Buntrock C, Cuijpers P. Increasing the clinical interpretability of PHQ-9 through equipercentile linking with health utility values by EQ-5D-3L. Evid Based Ment Health. 2021;24(4):e6.
  33. Vancak V, Goldberg Y, Levine SZ. Systematic analysis of the number needed to treat. Stat Methods Med Res. 2020;29(9):2393-2410.
  34. Rahman R, Kodesh A, Levine SZ, Sandin S, Reichenberg A, Schlessinger A. Identification of newborns at risk for autism using electronic medical records and machine learning. European psychiatry : the journal of the Association of European Psychiatrists. 2020;63(1):e22.
  35. Kodesh A, Sandin S, Reichenberg A, et al. Antidepressants and the Risk of Dementia: Appropriate Consideration of Confounding by Indication. Am J Geriatr Psychiatry. 2020;28(4):499-500.
  36. Kodesh A, Goldberg Y, Rotstein A, et al. Risk of dementia and death in very-late-onset schizophrenia-like psychosis: A national cohort study. Schizophr Res. 2020;223:220-226.
  37. Kan KJ, de Jonge H, van der Maas HLJ, Levine SZ, Epskamp S. How to Compare Psychometric Factor and Network Models. J Intell. 2020;8(4).
  38. Dinstein I, Arazi A, Golan HM, et al. The National Autism Database of Israel: a Resource for Studying Autism Risk Factors, Biomarkers, Outcome Measures, and Treatment Efficacy. J Mol Neurosci. 2020;70(9):1303-1312.
  39. Vinokur D, Levine SZ. Non-suicidal self-harm in prison: A national population-based study. Psychiatry Res. 2019;272:216-221.
  40. Rabinovitz S, Goldman K, Rosca P, Barda J, Levine SZ. The role of substance use and adult sexual assault severity in the course of schizophrenia: An epidemiological catchment study of sexual assault victims. Schizophr Res. 2019;208:406-413.
  41. Noma H, Maruo K, Gosho M, et al. Efficient two-step multivariate random effects meta-analysis of individual participant data for longitudinal clinical trials using mixed effects models. BMC Med Res Methodol. 2019;19(1):33.
  42. Kodesh A, Sandin S, Reichenberg A, et al. Exposure to Antidepressant Medication and the Risk of Incident Dementia. Am J Geriatr Psychiatry. 2019;27(11):1177-1188.
  43. Kodesh A, Levav I, Levine SZ. Exposure to Genocide and the Risk of Dementia. J Trauma Stress. 2019;32(4):536-545.
  44. Kan K-J, van der Maas HLJ, Levine SZ. Extending psychometric network analysis: Empirical evidence against g in favor of mutualism? Intelligence. 2019;73:52-62.
  45. Hansen SN, Schendel DE, Francis RW, et al. Recurrence Risk of Autism in Siblings and Cousins: A Multinational, Population-Based Study. J Am Acad Child Adolesc Psychiatry. 2019;58(9):866-875.
  46. Bai D, Yip BHK, Windham GC, et al. Association of Genetic and Environmental Factors With Autism in a 5-Country Cohort. JAMA Psychiatry. 2019;76(10):1035-1043.
  47. Weinstein Y, Levav I, Gelkopf M, et al. Association of maternal exposure to terror attacks during pregnancy and the risk of schizophrenia in the offspring: A population-based study. Schizophr Res. 2018;199:163-167.
  48. Viktorin A, Levine SZ, Altemus M, Reichenberg A, Sandin S. Paternal use of antidepressants and offspring outcomes in Sweden: nationwide prospective cohort study. BMJ. 2018;361:k2233.
  49. Smith L, Reichenberg A, Rabinowitz J, Levine SZ, Velthorst E. Psychiatric symptoms and related dysfunction in a general population sample. Schizophr Res Cogn. 2018;14:1-6.
  50. Rotstein A, Roe D, Gelkopf M, Shadmi E, Levine SZ. Quality of life disparities between persons with schizophrenia and their professional caregivers: Network analysis in a National Cohort. Schizophr Res. 2018;197:109-115.
  51. Rotstein A, Roe D, Gelkopf M, Levine SZ. Age of onset and quality of life among males and females with schizophrenia: A national study. European psychiatry : the journal of the Association of European Psychiatrists. 2018;53:100-106.
  52. Levine SZ, Kodesh A, Viktorin A, et al. Association of Maternal Use of Folic Acid and Multivitamin Supplements in the Periods Before and During Pregnancy With the Risk of Autism Spectrum Disorder in Offspring. JAMA Psychiatry. 2018;75(2):176-184.
  53. Leucht S, Levine SZ, Samara M, Cipriani A, Davis JM, Furukawa TA. Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why? European archives of psychiatry and clinical neuroscience. 2018;268(7):621-623.
  54. Janecka M, Kodesh A, Levine SZ, et al. Association of Autism Spectrum Disorder With Prenatal Exposure to Medication Affecting Neurotransmitter Systems. JAMA Psychiatry. 2018;75(12):1217-1224.
  55. Furukawa TA, Maruo K, Noma H, et al. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand. 2018;137(6):450-458.
  56. Davidovitch M, Chodick G, Shalev V, et al. Infertility treatments during pregnancy and the risk of autism spectrum disorder in the offspring. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:175-179.
  57. Weiser M, Levi L, Levine SZ, et al. A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. Bipolar Disord. 2017;19(4):285-294.
  58. Weinstein Y, Gelkopf M, Roe D, Levine SZ. The effect of different terror exposures on the course of schizophrenia: A twenty-year follow-up of a random sample. Schizophr Res. 2017;189:215-216.
  59. Viktorin A, Uher R, Reichenberg A, Levine SZ, Sandin S. Autism risk following antidepressant medication during pregnancy. Psychol Med. 2017;47(16):2787-2796.
  60. Viktorin A, Uher R, Kolevzon A, Reichenberg A, Levine SZ, Sandin S. Association of Antidepressant Medication Use During Pregnancy With Intellectual Disability in Offspring. JAMA Psychiatry. 2017;74(10):1031-1038.
  61. Samara MT, Goldberg Y, Levine SZ, et al. Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. Lancet Psychiatry. 2017;4(11):859-867.
  62. Bursztein Lipsicas C, Levav I, Levine SZ. Holocaust exposure and subsequent suicide risk: a population-based study. Soc Psychiatry Psychiatr Epidemiol. 2017;52(3):311-317.
  63. Madhoo M, Levine SZ. Network analysis of the Quick Inventory of Depressive Symptomatology: Reanalysis of the STAR*D clinical trial. Eur Neuropsychopharmacol. 2016;26(11):1768-1774.
  64. Levine SZ, Levav I, Yoffe R, Becher Y, Pugachova I. Genocide Exposure and Subsequent Suicide Risk: A Population-Based Study. PloS one. 2016;11(2):e0149524.
  65. Levine SZ, Levav I, Pugachova I, Yoffe R, Becher Y. Transgenerational effects of genocide exposure on the risk and course of schizophrenia: A population-based study. Schizophr Res. 2016;176(2-3):540-545.
  66. Levine SZ, Levav I, Goldberg Y, Pugachova I, Becher Y, Yoffe R. Exposure to genocide and the risk of schizophrenia: a population-based study. Psychol Med. 2016;46(4):855-863.
  67. Levine SZ, Leucht S. Identifying a system of predominant negative symptoms: Network analysis of three randomized clinical trials. Schizophr Res. 2016;178(1-3):17-22.
  68. Levine SZ, Kodesh A, Goldberg Y, et al. Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. European psychiatry : the journal of the Association of European Psychiatrists. 2016;32:16-20.
  69. Gelkopf M, Lapid L, Werbeloff N, et al. A strengths-based case management service for people with serious mental illness in Israel: A randomized controlled trial. Psychiatry Res. 2016;241:182-189.
  70. Yonai S, Levine S, Z., Glicksohn J. Trajectories of crime and familial characteristics: a longitudinal national population-based study. Crime and Delinquency. 2015;61(7):927–949.
  71. Wilson JE, Niu K, Nicolson SE, Levine SZ, Heckers S. The diagnostic criteria and structure of catatonia. Schizophr Res. 2015;164(1-3):256-262.
  72. Velthorst E, Reichenberg A, Rabinowitz J, Levine SZ. Study of resilience and environmental adversity in midlife health (STREAM). Soc Psychiatry Psychiatr Epidemiol. 2015;50(12):1915-1922.
  73. Madhoo M, Levine SZ. Initial Severity Effects on Residual Symptoms in Response and Remission: A STAR*D Study During and After Failed Citalopram Treatment. J Clin Psychopharmacol. 2015;35(4):450-453.
  74. Levine SZ, Rabinowitz J, Uher R, Kapur S. Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance. Eur Neuropsychopharmacol. 2015;25(10):1578-1585.
  75. Levine SZ, Goldberg Y, Samara M, Davis JM, Leucht S. Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. Schizophr Res. 2015;164(1-3):122-126.
  76. Furukawa TA, Levine SZ, Tanaka S, et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry. 2015;72(1):14-21.
  77. Vinokur D, Levine SZ, Roe D, Krivoy A, Fischel T. Age of onset group characteristics in forensic patients with schizophrenia. European psychiatry : the journal of the Association of European Psychiatrists. 2014;29(3):149-152.
  78. Russo M, Levine SZ, Demjaha A, et al. Association between symptom dimensions and categorical diagnoses of psychosis: a cross-sectional and longitudinal investigation. Schizophr Bull. 2014;40(1):111-119.
  79. Marques TR, Levine SZ, Reichenberg A, et al. How antipsychotics impact the different dimensions of Schizophrenia: a test of competing hypotheses. Eur Neuropsychopharmacol. 2014;24(8):1279-1288.
  80. Levine SZ, Levav I, Yoffe R, Pugachova I. The effects of pre-natal-, early-life- and indirectly-initiated exposures to maximum adversities on the course of schizophrenia. Schizophr Res. 2014;158(1-3):236-240.
  81. Levine SZ, Leucht S. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. Schizophr Res. 2014;156(1):107-114.
  82. Levine SZ. Low birth-weight and risk for major depression: a community-based longitudinal study. Psychiatry Res. 2014;215(3):618-623.
  83. Yonai S, Levine SZ, Glicksohn J. A national population based examination of the association between age-versatility trajectories and recidivism rates. Journal of Criminal Justice. 2013;41(6):467-476.
  84. Velthorst E, Levine SZ, Henquet C, et al. To cut a short test even shorter: reliability and validity of a brief assessment of intellectual ability in schizophrenia--a control-case family study. Cogn Neuropsychiatry. 2013;18(6):574-593.
  85. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Comparing symptom response among antipsychotic medications in CATIE. J Clin Psychopharmacol. 2013;33(1):123-126.
  86. Levine SZ, Leucht S. Psychometric analysis in support of shortening the Scale for the Assessment of Negative Symptoms. Eur Neuropsychopharmacol. 2013;23(9):1051-1056.
  87. Levine SZ, Leucht S. Attaining and sustaining remission of predominant negative symptoms. Schizophr Res. 2013;143(1):60-64.
  88. Levine SZ, Leucht S. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. Schizophr Res. 2013;145(1-3):125-127.
  89. Levine SZ. Evaluating the seven-item Center for Epidemiologic Studies depression scale short-form: a longitudinal U.S. community study. Soc Psychiatry Psychiatr Epidemiol. 2013;48(9):1519-1526.
  90. Garber-Epstein P, Zisman-Ilani Y, Levine S, Roe D. Comparative impact of professional mental health background on ratings of consumer outcome and fidelity in an Illness Management and Recovery program. Psychiatr Rehabil J. 2013;36(4):236-242.
  91. Furnham A, Guenole N, Levine SZ, Chamorro-Premuzic T. The NEO Personality Inventory-Revised: factor structure and gender invariance from exploratory structural equation modeling analyses in a high-stakes setting. Assessment. 2013;20(1):14-23.
  92. Bensimon M, Levine SZ, Zerach G, Stein E, Svetlicky V, Solomon Z. Elaboration on posttraumatic stress disorder diagnostic criteria: a factor analytic study of PTSD exposure to war or terror. The Israel journal of psychiatry and related sciences. 2013;50(2):84-90.
  93. Werbeloff N, Levine SZ, Rabinowitz J. Elaboration on the association between immigration and schizophrenia: a population-based national study disaggregating annual trends, country of origin and sex over 15 years. Soc Psychiatry Psychiatr Epidemiol. 2012;47(2):303-311.
  94. Walsh SD, Levine SZ, Levav I. The association between depression and parental ethnic affiliation and socioeconomic status: a 27-year longitudinal US community study. Soc Psychiatry Psychiatr Epidemiol. 2012;47(7):1153-1158.
  95. Ullman VZ, Levine SZ, Reichenberg A, Rabinowitz J. Real-world premorbid functioning in schizophrenia and affective disorders during the early teenage years: a population-based study of school grades and teacher ratings. Schizophr Res. 2012;136(1-3):13-18.
  96. Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137(1-3):147-150.
  97. Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H. Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophr Res. 2012;137(1-3):141-146.
  98. Levine SZ, Leucht S. Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia. Schizophr Res. 2012;141(2-3):168-172.
  99. Levine SZ, Leucht S. Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. Eur Neuropsychopharmacol. 2012;22(11):812-817.
  100. Levine SZ, Rabinowitz J, Rizopoulos D. Recommendations to improve the positive and negative syndrome scale (PANSS) based on item response theory. Psychiatry Res. 2011;188(3):446-452.
  101. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res. 2011;133(1-3):42-46.
  102. Levine SZ, Lurie I, Kohn R, Levav I. Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophr Res. 2011;126(1-3):184-191.
  103. Levine SZ. Elaboration on the association between IQ and parental SES with subsequent crime. Personality and Individual Differences. 2011;50(8):1233-1237.
  104. Hultman CM, Sandin S, Levine SZ, Lichtenstein P, Reichenberg A. Advancing paternal age and risk of autism: new evidence from a population-based study and a meta-analysis of epidemiological studies. Mol Psychiatry. 2011;16(12):1203-1212.
  105. Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, Poyurovsky M. Adherence to antipsychotic drug treatment in early-episode schizophrenia: a six-month naturalistic follow-up study. Schizophr Res. 2011;130(1-3):176-181.
  106. Yonai S, Levine SZ, Glicksohn J. Elaboration on Specialization in Crime. Crime Delinquency. 2010;59(6):951-970.
  107. Rabinowitz J, Levine S, Martinez G. Concordance between measures of functioning, symptoms, and change: examining the GAF, CGI-S, CGI-C, and PANSS. J Clin Psychopharmacol. 2010;30(4):478-480.
  108. Mansbach-Kleinfeld I, Apter A, Farbstein I, Levine SZ, Ponizovsky AM. A population-based psychometric validation study of the strengths and difficulties questionnaire - hebrew version. Front Psychiatry. 2010;1(51):151.
  109. Lurie I, Levine SZ. Meta-analysis of dropout rates in SSRIs versus placebo in randomized clinical trials of PTSD. The Journal of nervous and mental disease. 2010;198(2):116-124.
  110. Levine SZ, Rabinowitz J, Case M, Ascher-Svanum H. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study. J Clin Psychopharmacol. 2010;30(4):446-449.
  111. Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull. 2010;36(3):624-632.
  112. Levine SZ, Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry. 2010;68(1):86-92.
  113. Levine SZ, Bakst S, Rabinowitz J. Suicide attempts at the time of first admission and during early course schizophrenia: a population based study. Psychiatry Res. 2010;177(1-2):55-59.
  114. Laufer A, Solomon Z, Levine SZ. Elaboration on posttraumatic growth in youth exposed to terror: the role of religiosity and political ideology. Soc Psychiatry Psychiatr Epidemiol. 2010;45(6):647-653.
  115. Rabinowitz J, Levine SZ, Barkai O, Davidov O. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull. 2009;35(4):775-788.
  116. Levine SZ, Rabinowitz J. A population-based examination of the role of years of education, age of onset, and sex on the course of schizophrenia. Psychiatry Res. 2009;168(1):11-17.
  117. Levine SZ, Laufer A, Stein E, Hamama-Raz Y, Solomon Z. Examining the relationship between resilience and posttraumatic growth. J Trauma Stress. 2009;22(4):282-286.
  118. Levine SZ. Examining the Incidence of and Time to Recidivism Within the Risk Contingency Framework: A 20-Year Follow up Study. Law and Human Behavior. 2009;33(2):167–174.
  119. Laufer A, Raz-Hamama Y, Levine SZ, Solomon Z. Posttraumatic Growth in Adolescence: The Role of Religiosity, Distress, and Forgiveness. Journal of Social and Clinical Psychology. 2009;28(7):862-880.
  120. Brill N, Levine SZ, Reichenberg A, Lubin G, Weiser M, Rabinowitz J. Pathways to functional outcomes in schizophrenia: the role of premorbid functioning, negative symptoms and intelligence. Schizophr Res. 2009;110(1-3):40-46.
  121. Rabinowitz J, Levine SZ, Medori R, Oosthuizen P, Koen L, Emsley R. Concordance of patient and clinical ratings of symptom severity and change of psychotic illness. Schizophr Res. 2008;100(1-3):359-360.
  122. Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S. Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI. Schizophr Res. 2008;98(1-3):318-322.
  123. Levine SZ, Laufer A, Hamama-Raz Y, Stein E, Solomon Z. Posttraumatic growth in adolescence: examining its components and relationship with PTSD. J Trauma Stress. 2008;21(5):492-496.
  124. Levine SZ. Population-based examination of the relationship between type of first admission for schizophrenia and outcomes. Psychiatric Services. 2008;59(12):1470-1473.
  125. Levine SZ. Using intelligence to predict subsequent contacts with the criminal justice system for sex offences. Personality and Individual Differences. 2008;44(2):453-463.
  126. Rabinowitz J, Levine SZ, Haim R, Hafner H. The course of schizophrenia: progressive deterioration, amelioration or both? Schizophr Res. 2007;91(1-3):254-258.
  127. Rabinowitz J, Levine SZ, Brill N, Bromet EJ. The premorbid adjustment scale structured interview (PAS-SI): preliminary findings. Schizophr Res. 2007;90(1-3):255-257.
  128. Levine SZ, Rabinowitz J. Revisiting the 5 dimensions of the Positive and Negative Syndrome Scale. J Clin Psychopharmacol. 2007;27(5):431-436.
  129. Levine SZ. Handbook of multimethod measurement in psychology. British Journal of Mathematical & Statistical Psychology. 2007;60:194-196.
  130. Rabinowitz J, Levine SZ, Hafner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr Res. 2006;88(1-3):96-101.
  131. Levine SZ, Petrides KV, Davis S, Jackson CJ, Howell P. The Use of Structural Equation Modeling in Stuttering Research: Concepts and Directions. Stammering Res. 2005;1(4):344-363.
  132. Levine SZ, Jackson CJ. Eysenck's theory of crime revisited: Factors or primary scales? Legal and Criminological Psychology. 2004;9(1):135-152.
  133. Petrides KV, Jackson CJ, Furnharn A, Levine SZ. Exploring issues of personality measurement and structure through the development of a short form of the Eysenck Personality Profiler. Journal of Personality Assessment. 2003;81(3):271-280.
  134. Jackson CJ, Levine SZ, Furnham A. Gray's model of personality and aggregate level factor analysis. European Journal of Personality. 2003;17(5):397-411.
  135. Levine SZ, Jackson CJ. Aggregated personality, climate and demographic factors as predictors of departmental shrinkage. Journal of Business and Psychology. 2002;17(2):287-297.
  136. Jackson CJ, Levine SZ, Furnham A, Burr N. Predictors of Cheating Behavior at a University: A Lesson From the Psychology of Work. Journal of Applied Social Psychology. 2002;32(5):1031-1046.

  

Book Chapters  

  1. Sandin S, Kolevzon A, Levine S. Z., Hultman CM, Reichenberg A. (2012). Parental and Perinatal Risk Factors for Autism: Epidemiological Findings and Potential Mechanisms. In J. D. Buxbaum & P. R. Hof (Eds.), The Neuroscience of Autism Spectrum Disorders. San Diego: Academic Press.

  2. *Yonai, S., Ashira, Z., & Levine, S. Z. (2009). Creating a deterrence effect by DNA testing among criminals The Fundamentals of Research 2009: Research and Literature Reviews of the Activities of the Israeli Police Force. A Collection of Articles. Jerusalem: Israeli Police Force (In Hebrew).

  3. *Ziv, N., Levine, S. Z., & *Yonai, S. (2009). The effect of geographical distance from the war-zone on the crime rate. The Fundamentals of Research 2009: Research and Literature Reviews of the Activities of the Israeli Police Force. A Collection of Articles. Jerusalem: Israeli Police Force (In Hebrew).

  4. Werner, S., Levine, S. Z., & Rabinowitz, J. (2008). The course of schizophrenia: The natural course of schizophrenia: progressive deterioration, amelioration or both? In Y. Teller (Ed.), Upwards: Chapters in Community Mental Health. Haifa: Ahvah Publishers (In Hebrew).

  5. Rabinowitz, J., & Levine, S. Z. (2007). Epidemiología de la esquizofrenia: inicio y curso: Elsevier-Masson. In J. L.Vázquez-Barquero & B. Crespo-Facorro (Eds.), Nuevos enfoques para la intervención en primeros episodios de psicosis. Milan: Elsevier Masson (In Spanish).

  6. Petrides, K. V., Jackson, C. J., Furnham, A., & Levine, S. Z. (2004). Development of a Short Form of the Eysenck Personality Profiler via Structural Equation Modelling. In K. van Monford, J. Oud & A. Satorra (Eds.), Recent developments in structural equation modeling: Theory and applications. Dordrecht: Kluwer Academic Publishers.

Papers Presented at International and National Conferences

  1. Kodesh, A., Herkovitz, P., Levine, S., Z. (2018). Prevalence and comorbidities of dementia in Israel: A nationally representative study. Annual conference of the ISQ- Israel Society for Quality November 20-21, 2018. David Intercontinental Hotel, Tel Aviv, Israel.

  2. Janecka, M., Kodesh, A., Levine, S., Z., Lusskin, S., Viktorin, A., Rahman, R., Buxbaum, J., Schlessinger, A., Sandin, S., & Reichenberg. (2018). A.Neurotransmitter-Wide Association Study of Prenatal Exposure to Medication With Autism Spectrum Disorder. 73rd Annual Scientific Convention and Meeting. Annual Meeting of the Society of Biological Psychiatry.

  3. Levine, S. Z., Kodesh, A., Viktorin, A., Reichenberg, A., & Sandin, S. (2018). Association of maternal use of folic acid and multivitamin supplements in the periods before and during pregnancy with the risk of Autism Spectrum Disorder in offspring. Israeli Psychiatric Association. 31 May, Tel Aviv.

  4. Kodesh, A., & Levine, S.Z. (2018). Association of maternal use of folic acid and multivitamin supplements in the periods before and during pregnancy with the risk of Autism Spectrum Disorder in offspring. National Institute for Health Policy Research. 9 May, Tel Aviv

  5. Levine, S. Z., & Leucht, S. (2017) Network Analysis of the SANS: Analysis of Three Randomized Clinical Trials of Predominant Negative Symptoms. The 15th International Congress for Schizophrenia Research, San Diego, US (Approximately 1 page)

  6. Levine, S. Z., & Leucht, S. (2016). Toward a Negative symptom system of Schizophrenia: A network approach. The Fifth Biannual Schizophrenia International Research Society Conference. Florence, Italy. (Approximately half a page).

  7. Levine, S. Z., Goldberg, Y., Samara, M., Davis, J., & Leucht, S. (2016). Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. The Fifth Biannual Schizophrenia International Research Society Conference. Florence, Italy. (Approximately half a page).

  8. Kodesh, A., Levine, S.Z., Valinsky, L., Hershkowitz-Sikron, F. (2016). The course of diabetes in schizophrenia: An epidemiological study. The Fifth Biannual Schizophrenia International Research Society Conference. Florence, Italy. (Approximately half a page).

  9. Levine, S. Z., Furukawa, T, Tanaka, S., Goldberg, Y., Samara, M., Davis, J., Cipriani A., Leucht S. (2015). Initial severity in the treatment of schizophrenia. Talk at: Fourth International Congress on Schizophrenia Research, Spring Falls, USA.

  10. Niu, K., Wilson, J., Heckers, S., & Levine, S.Z (2014, February 15 – 18). Psychometric Properties of the Bush Francis Catatonia Rating Scale. Paper presented at the Journal of Neuropsychiatry and Clinical Neurosciences, Washington DC, USA.

  11. Levine, S. Z., Kolevzon, A., & Reichenberg. (2014). Past and Future Trends of Clinical Trials for Autism Spectrum Disorders. Paper presented at the International Society for CNS Clinical Trials and Methodology 2014 Autumn Conference. Washington DC, USA.

  12. Levine, S. Z., Rabinowitz, J., Caers, I., Mandel, F., Menard, F., Kapur, S. (2013). Item Response Theory analysis of the PANSS from the NewMeds repository from 49 RCTs. Talk presented at the 14th International Congress for Schizophrenia Research, Orlando, US.

  13. Levine, S. Z., Ascher-Svanum, H., Faries, D. E., Lawson, A. H., & Rabinowitz, J. (2012). Comparing Symptom Response among Antipsychotic Medications in CATIE. Paper presented at the 3rd Biennial Schizophrenia International Research Conference, Florence, Italy.

  14. Levine, S. Z. and S. Leucht (2012). What does the SANS mean? Paper presented at the International Society for CNS Clinical Trials and Methodology 2012 Autumn Conference. Marina del Rey, USA.

  15. Levine, S. Z., Yoffe, R., Pugachova, I., & Reichenberg, A. (2012). Familial and genetic factors in the trajectories of the course of serious mental illness: A national population-based twin study. Paper presented at the 3rd Biennial Schizophrenia International Research Conference, Florence, Italy.

  16. Davidson, M., Reichenberg, A., Levine, S. Z., Rabinowitz, J., Keefe, R., Murray, R., Moffitt, T., & Caspi, A. (2011). Modeling the expression and course of developmental abnormalities preceding adult schizophrenia: characterization of a new developmental ultra-high-risk group in 2 birth cohorts. Paper presented at the 13th International Congress on Schizophrenia Research, Colorado Springs, USA.

  17. Levine, S. Z., Rabinowitz J, Ascher-Svanum H, Faries, D. E., Lawson A. H. (2011).  Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study. Poster presented at the ISPOR 14th Annual European Congress Madrid, Spain.

  18. Levine, S. Z., Rabinowitz J, Ascher-Svanum H, Faries, D. E., Lawson A. H. (2011). Treatment Response Trajectories and Antipsychotic Medication in the Treatment of Chronic Schizophrenia. The 164th Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii.

  19. Rabinowitz, J., Garibaldi, G., Levine, S. Z., Bugarski-Kirola, D., Berardo C., Kapur S. (2011). Negative symptoms have greater impact on functioning than positive sympoms in schizophrenia: Analysis of the CATIE data. Poster presented at the ISPOR 14th Annual European Congress Madrid, Spain.

  20. Russo, M., Levine, S. Z., Demjaha, A., Di Forti, M., Mondelli, V., Belvederi-Murri, M., Wiffen, B., Dazzan, P., Fearon, P., Morgan, C., Murray, R., Reichenberg, A. (2011). The hierarchical organization of symptom dimensions in first episode psychosis and the relationship to diagnostic classification. The 13th International Congress on Schizophrenia Research, Colorado Springs, USA.

  21. Levine, S. Z., Bakst, S., & Rabinowitz, J. (2010). Suicide Attempts at the time of First admission and during Early Course Schizophrenia: A Population Based Study. The Second Schizophrenia International Research Society Conference. Italy.

  22. Rabinowitz, J., Levine, S. Z., & Martinez, G. (2010). Concordance between measures of functioning, symptomatology and change: GAF, CGI-S, CGI-C and PANSS. The Second Schizophrenia International Research Society Conference, Italy.

  23. Ulman, V., Levine, S. Z., & Rabinowitz, J. (2010). A population-based elaboration on premorbid functioning in schizophrenia during the early teenage years: Comparison, incident and onset. The Second Schizophrenia International Research Society Conference, Italy.

  24. Werbeloff, N., Levine, S. Z., & Rabinowitz, J. (2010). Elaboration on the association between immigration and schizophrenia: a population based national study. The 23rd European College of Neuropsychopharamcology Conference. Amsterdam.

Journal Reviewer
Editorial board member: European Neuropsychopharmacology (IF= 4.239).
Academic editorial board member: PLoS One (2018-2022).
International Editorial Advisory Board: International Journal of Criminal Justice Sciences

Ad hoc reviewer (65 + journals): Accident Analysis and Prevention, Acta Psychiatrica Scandinavica, Administrative Policy in Mental Health and Mental Health Services Research, African Journal of Pharmacy and Pharmacology, American Journal of Psychiatry, Australian Journal of Psychology, Basic and Applied Psychology, Biological Psychiatry, BMC Psychiatry, BMC Psychology, BMC Medical Research Methodology, BMJ Open, British Journal of Clinical Pharmacology, British Journal of Psychiatry, Canadian Journal of Psychiatry, Conflict and Health, CNS Spectrums, Crime and Delinquency, Current Research and Medical Opinion, Development and Psychopathology, Epidemiology Open Access, Epidemiology and Psychiatric Sciences, European Psychiatry, European Neuropsychopharmacology, Human Psychopharmacology: Clinical and Experimental, International Journal of Developmental Neuroscience, International Journal of Comparative & Applied Criminal Justice, International Journal of Epidemiology, International Journal of Methods in Psychiatric Research, International Journal of Psychology, International Psychogeriatrics, International Journal of Stress Management, Israeli Journal of Psychiatry and Related Disorders, Molecular Psychiatry, JAMA Neurology, JAMA Psychiatry, Journal of Adolescent Health, Journal of Affective Disorders, Journal of Autism and Developmental Disorders, Journal of Behavioral Health, Journal of Clinical Epidemiology, Journal of Clinical Psychopharmacology, Journal of Traumatic Stress, Journal of Experimental Criminology, Journal of Applied Social Psychology, Journal of Immigrant and Minority Health, Journal of Pediatric Neurology, Journal of Trauma & Disassociation, Justice Quarterly, Military Medicine, Molecular Psychiatry, Neuropsychiatric Disease and Treatment, New England Journal of Medicine, Lancet Psychiatry, Legal and Criminological Psychology, Nordic Journal Of Psychiatry, Personality and Individual Differences, PLOS ONE, Psychiatry Research, Psychopathology, Psychological Assessment, Psychological Medicine, Psychological Reports, Psychopharmacology, Psychosis, Schizophrenia Bulletin, Schizophrenia Research, Social Psychiatry and Psychiatric Epidemiology, Stigma and Health, Translational Psychiatry, Violence and Victims, The World Journal of Biological Psychiatry.

Other reviewing activities
Grant reviewer- German Israel Foundation, Hong Kong SAR Government - Health and Health Services Research Fund, Israel National Institute for Health Policy Research, Israel Cancer Association, Israel Science Foundation, Netherlands Organisation for Scientific Research.
Conferences- Israeli Psychometric Association (Reviewer: 2010-2019; 2014 Reviewer & invited session chair). ISPOR 6th Asia-Pacific Conference, China (2014) - Abstract reviewer.


Professional Membership
Current- Israeli Psychometric Association, Schizophrenia International Research Society, International Society for Clinical Trials and Methodology (ISCTM).
Past- International Society for the Study of Individual Differences, European College of Neuropsychopharmacology.

Computing skills
R (since 2006, advanced), SPSS (advanced), SAS (moderate), Microsoft Office.

All rights reserved © Faculty of Social Welfare & Health Sciences, University of Haifa
199 Aba Khoushy Ave. Mount Carmel, Haifa, Israel - 3498838
Images from istockphoto Webmaster